Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. (IMDX) Revenue
Annual & quarterly revenue history · segment & region breakdown
IMDX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsInsight Molecular Diagnostics Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 115.58% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2013 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | +$0.00B | +115.58% |
| 2024-12-31 | $0.00B | +$0.00B | +25.15% |
| 2023-12-31 | $0.00B | +$0.00B | +56.89% |
| 2022-12-31 | $0.00B | -$0.00B | -56.41% |
| 2021-12-31 | $0.00B | +$0.00B | +80.76% |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Insight Molecular Diagnostics Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Insight Molecular Diagnostics Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Insight Molecular Diagnostics Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IMDX revenue · 4 questionsIMDX's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 115.58% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Insight Molecular Diagnostics Inc. SEC filings · GAAP · Insight Molecular Diagnostics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026